Testosterone and Body Composition After 40: What the Research Actually Shows

There is a frustrating pattern that many men in their 40s describe in similar terms: they are training as hard as they were in their 30s, eating the same way, and yet the testosterone body composition relationship seems to have quietly shifted against them. Muscle is harder to build and easier to lose. Fat accumulates in the abdomen despite no clear change in diet. Recovery from training takes longer. The assumption is usually that this is simply aging, and the advice that follows is usually to train harder and eat cleaner. What is rarely discussed is the hormonal physiology behind what is actually happening, and what the evidence says about whether it can be meaningfully addressed. For a comprehensive look at how testosterone decline presents clinically, the NIH StatPearls chapter on Hypogonadism provides detailed background on mechanisms and criteria.

This article covers the testosterone body composition relationship in depth: how testosterone affects muscle and fat at a physiological level, what the research actually shows about the effects of testosterone therapy on body composition in men over 40, what factors predict who responds most, how exercise interacts with testosterone in this context, and what the honest picture looks like when you separate the clinical evidence from the marketing. For a broader overview of how hormone therapy and peptides work together, the Complete Beginner’s Guide to Peptide Therapy covers the full landscape.

How Testosterone Affects Body Composition in Men Over 40

Testosterone’s influence on body composition operates through several distinct mechanisms that together explain why its decline has visible consequences for how men look and feel as they age.

The most direct pathway involves muscle protein synthesis. Testosterone binds to androgen receptors in skeletal muscle cells and upregulates the signaling cascades that drive muscle protein production, satellite cell activation, and muscle fiber hypertrophy. When testosterone is adequate, the anabolic response to training stimuli is more robust. When testosterone declines, that response diminishes even when training volume and intensity remain constant. This is not a motivational or effort-related phenomenon. It is a biological change in how efficiently muscle tissue responds to mechanical loading.

On the fat side, the relationship is equally direct and importantly bidirectional. Testosterone promotes lipolysis (the breakdown of stored fat for energy) and suppresses lipogenesis (the creation of new fat cells), particularly in visceral adipose tissue. When testosterone falls, visceral fat accumulates. This is clinically significant because visceral fat is not metabolically inert. It is metabolically active tissue that contains the enzyme aromatase, which converts testosterone into estrogen. The result is a self-reinforcing cycle: low testosterone promotes visceral fat gain, and the growing visceral fat tissue further suppresses testosterone by increasing aromatase activity and estrogen production. This bidirectional relationship was documented in the research by Grossmann et al. in the Journal of Clinical Endocrinology and Metabolism in 2011 and has been replicated across multiple study populations since.

Finkelstein and colleagues demonstrated the testosterone-fat relationship directly in a landmark 2013 New England Journal of Medicine study that experimentally suppressed testosterone in healthy young men and then replaced it at different doses. As testosterone was suppressed, fat mass increased in a dose-dependent manner: the lower the testosterone, the greater the fat accumulation, particularly in the trunk. When testosterone was replaced, fat mass decreased. This controlled suppression-and-replacement design removed the confounders that affect observational studies and confirmed that the relationship between testosterone and fat mass is causally significant, not merely correlational.

What Happens to Testosterone and Body Composition After 40

Testosterone levels peak in the late teens and early 20s and then decline at approximately 1 to 2 percent per year after age 30 to 40. By the time men are in their mid-40s, testosterone may be 20 to 30 percent below its lifetime peak. By age 60, roughly 20% of men have testosterone levels below clinical thresholds for hypogonadism. By age 70 that proportion rises to 30%, and by age 80 to approximately 50%.

These numbers reflect a range that is wide enough that many men in their 40s still have testosterone within formal reference ranges while experiencing meaningful decline from their personal baseline. The reference range defines a population distribution, not an individual’s optimal level. A man whose testosterone was 800 ng/dL at age 28 and now tests at 350 ng/dL at age 47 is technically “normal” but has lost more than half his hormonal baseline and will likely experience the body composition changes associated with that loss despite a result that does not flag as low on a lab report.

This is one of the reasons free testosterone and SHBG matter in this conversation. As men age, SHBG (sex hormone-binding globulin) tends to increase, binding more testosterone and reducing the biologically active free fraction. A man can have a normal total testosterone but meaningfully low free testosterone if SHBG is elevated, which produces the same physiological consequences as absolute testosterone deficiency without triggering the standard diagnostic threshold.

What the Research Shows About TRT and Body Composition

The evidence base for testosterone replacement therapy and body composition is one of the most well-developed in hormone research, with multiple meta-analyses and large controlled trials available for analysis. The honest summary is that the effects on testosterone body composition are real, clinically meaningful in hypogonadal men, and most pronounced when baseline testosterone is confirmed low.

Meta-Analyses on Testosterone Body Composition: What They Found

A meta-analysis by Isidori and colleagues examined 29 randomized controlled trials and found that testosterone therapy in middle-aged men produced statistically significant reductions in fat mass and significant increases in lean body mass. The direction of effect was consistent across trials even when the magnitude varied by formulation and baseline testosterone level.

A separate meta-analysis of 31 RCTs found that intramuscular testosterone therapy increased fat-free mass by an average of 5.7% and improved muscle strength by 10 to 13% in middle-aged and older men. In overweight and obese men with confirmed testosterone deficiency, testosterone therapy led to approximately 2.9 kg greater fat mass loss and 3.4 kg greater lean mass gain compared to placebo over 56 weeks.

A 2025 narrative review published in Cureus specifically examining TRT in men aged 40 to 49 found that trials in this age group reported clinically meaningful increases in lean mass of 2 to 4 kg and reductions in fat mass of 2 to 3 kg over 6 to 12 months of therapy, particularly with intramuscular formulations in men with documented biochemical hypogonadism.

Who Responds Most: Testosterone Body Composition Predictors

Not all men on testosterone therapy see the same body composition response, and the research is clear about which factors predict better outcomes. A secondary analysis published in Frontiers in Endocrinology examining 105 men aged 40 to 74 on testosterone therapy for 18 months found that men with the lowest baseline testosterone (below 264 ng/dL) showed significantly greater increases in fat-free mass at 18 months compared to men whose baseline was higher. The body composition benefit of TRT is not uniform across all testosterone levels. It is most pronounced in men who are genuinely deficient.

The Endocrine Society Clinical Practice Guideline, which represents the standard of care for testosterone therapy, recommends TRT for symptomatic hypogonadism confirmed by laboratory testing, not as a general body composition intervention in men with normal testosterone levels. For men who are overweight but not hypogonadal, the evidence for body composition benefit is considerably less consistent.

Exercise and the Testosterone Body Composition Equation

One of the most consistent findings across the research is that testosterone therapy and resistance training work synergistically. Each is effective alone in hypogonadal men, but their combination produces body composition outcomes superior to either intervention in isolation.

The mechanism is straightforward. Testosterone upregulates androgen receptors in muscle tissue and increases satellite cell activation, making muscle cells more responsive to training stimuli. Resistance training independently increases androgen receptor density and upregulates the anabolic signaling cascades that testosterone uses. When both are present simultaneously, the anabolic response to each training session is amplified. Conversely, testosterone therapy without an adequate training stimulus still produces body composition changes, but they are more modest and slower than when exercise is included.

The practical implication is that TRT is not a passive intervention for body composition. It changes the hormonal environment in which training occurs, making training more effective. For men who are already training consistently but not seeing expected progress, this is often the most compelling part of the conversation when they discuss testosterone with a licensed provider. It reframes the clinical question from “should I replace my testosterone” to “is my testosterone level a limiting factor in how my body responds to the work I am already doing.”

What the Research on Testosterone Body Composition Leaves Out

The research on testosterone and body composition is real. But several important qualifications are consistently omitted from the way this topic is discussed in wellness and supplement marketing contexts.

Getting the Baseline Right Before Any Testosterone Body Composition Protocol

The starting point for any conversation about testosterone and body composition is a comprehensive baseline evaluation. This includes morning total and free testosterone (morning draw, 7 to 10 AM), SHBG, estradiol, LH and FSH to distinguish primary from secondary hypogonadism, a complete metabolic panel, CBC with hematocrit, PSA for men over 40, and a lipid panel. IGF-1 is also relevant for men where GH-axis decline may be contributing to the body composition changes alongside testosterone, which is a common pattern in men over 50. For men where GH-axis support is part of the clinical picture, the Sermorelin guide explains how GH secretagogues fit alongside testosterone protocols.

The complete pre-therapy lab picture is covered in the companion article, What Labs Do You Need Before Starting Peptide Therapy. For men exploring how peptide options including GH secretagogues intersect with TRT for body composition, the article on Can Peptides Replace TRT addresses that question directly.